title: Neutrophil adhesion and activation during systemic thrombolysis in acute myocardial infarction.
abstract: In a pilot study, alterations of polymorphonuclear neutrophil function during systemic thrombolysis in acute myocardial infarction have been investigated in humans. The following parameters of neutrophil function were measured before and at 15 and 45 minutes after initiation of systemic thrombolysis with a recombinant tissue-type plasminogen activator in 20 patients with acute myocardial infarction: (1) neutrophil adhesion and (2) neutrophil activation. During systemic thrombolysis a significant decrease was observed in neutrophil adhesion (5.5+/-6.4 to 3.2+/-3.3; p<0.05), in phagocyting neutrophil activation (39+/-18 to 25+/-14%; p<0.05), and in resting neutrophil activation (9+/-7 to 3+/-4%; p<0.05). Successful reperfusion coincided with a significantly higher reduction of phagocyting neutrophil activation (40+/-14 to 20+/-12% vs. 39+/-24 to 26+/-19% in unsuccessful reperfusion; p<0.05), and of neutrophil adhesion (6.2+/-5.7 to 2.7+/-3.0 vs. 4.1+/-3.8 to 3.5+/-4.0 in unsuccessful reperfusion; p<0.05) during thrombolysis. Systemic thrombolysis in acute myocardial infarction is accompanied by a reduction in neutrophil adhesion and activation dependent on thrombolytic success.
authors.affiliation: Innere Medizin III, Department of Cardiology/Angiology, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Link
authors.forename: H
authors.initials: H
authors.lastname: Schwerdt
authors.forename: G
authors.initials: G
authors.lastname: Berg
authors.forename: A
authors.initials: A
authors.lastname: Link
authors.forename: U
authors.initials: U
authors.lastname: Maurer
authors.forename: G
authors.initials: G
authors.lastname: Neher
authors.forename: H
authors.initials: H
authors.lastname: Schieffer
mesh_terms: D000208:Acute Disease; D000368:Aged; D002448:Cell Adhesion; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000473:pathology; D015425:Myocardial Reperfusion; D018375:Neutrophil Activation / Q000187:drug effects*; D009504:Neutrophils / Q000473:pathology*; D011994:Recombinant Proteins / Q000008:administration & dosage; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator